Get a high resolution logo for any domain or stock ticker — for free

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction. In addition, its pre-clinical product is Sirolimus for prevention of organ transplant rejection. Further, the company focuses on the commercialization of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquatered in Uppsala, Sweden.